Johnson & Johnson: Hepatitis B, Chronic trials

The registry lists 19 Hepatitis B, Chronic studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 8 have results posted.

Early Phase 1 1Phase 1 9Phase 2 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B ParticipantsCompletedNCT05275023Phase 2Results posted
• A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus InfectionTerminatedNCT05005507Phase 2Results posted
• A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedNCT04667104Phase 2Results posted
• A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedNCT04585789Phase 2Results posted
• A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedNCT04439539Phase 2Results posted
• A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedNCT04129554Phase 2Results posted
• A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionCompletedNCT03982186Phase 2Results posted
• An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT03361956Phase 2Results posted
• A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) TreatmentWithdrawnNCT05550519Early Phase 1
• A Single and Multiple Ascending Dose Study of JNJ-64457744TerminatedNCT05423106Phase 1
• A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT05242445Phase 1
• A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionCompletedNCT05123599Phase 1
• A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically SuppressedCompletedNCT03463369Phase 1
• A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis BCompletedNCT03439488Phase 1
• A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B SubjectsWithdrawnNCT03125213Phase 2
• Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy VolunteersTerminatedNCT03032536Phase 1
• A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)CompletedNCT02662712Phase 1
• Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV PatientsCompletedNCT02401737Phase 1
• Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B PatientsCompletedNCT02112799Phase 1